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Abstract. The presence of four different isoforms of luteinizing
hormone-releasing hormones (LHRH) and one LHRH receptor
(LHRH-R) has been reported in vertebrates. In the human
genome only LHRH-I and LHRH-II genes have been
identified. The human LHRH-I gene is composed of four
exons separated by three introns. Three LHRH receptor or
receptor-like genes have been demonstrated. The well-
established type-I LHRH receptor (LHRH-R-I) gene is
composed of three exons separated by two introns. In this
study we investigated the expression of transcript forms of
LHRH-R-I in human benign prostatic hyperplasia (BPH)
with reverse transcriptase-polymerase chain reaction (RT-PCR)
using gene specific primers. Thirty-five human BPH specimens
were obtained at surgery. Normal human pituitaries collected
at autopsy served as control. RNA extraction and RT-PCR
with gene-specific primers for LHRH-R-I forward (F1)/reverse
(R1), LHRH-R-I F2/R3, LHRH-R-I F1'/R2' were carried out
to determine the mRNA expression for LHRH-R-I transcript
forms. The expected PCR products amplified with gene
specific primers were LHRH-R-I F1/R1 with 319 bp, LHRH-
R-I F2/R3 with 309 bp and LHRH-R-I F1'/R2' with 219 bp.
PCR products for LHRH-R-I F1/R1 were detected in 21 (60%)
and for LHRH-R-I F2/R3 in 5 of 35 (14%) BPH samples.
No PCR products for LHRH-R-I F1'/R2' were found. In
conclusion, we detected mRNA for LHRH-R-I in human
BPH specimens. Our results suggest that LHRH-R-I gene
may have more than two splice variants or uncharacterised
transcript forms of LHRH-R-I. Our findings support the merit
of further investigation of the expression of LHRH-R-I and
its transcript forms in human BPH.
Introduction
Luteinizing hormone-releasing hormone-I (LHRH-I), also
known as gonadotropin hormone-releasing hormone, (GnRH)
is the primary link between the brain and the pituitary in the
regulation of gonadal function and plays a pivotal role in
vertebrate reproduction (1). The discovery of LHRH has
had a major impact on medicine and has led to a variety of
clinical uses of LHRH analogs in oncology and gynecology
(1). Most vertebrates express at least two LHRH isoforms.
In the human genome only LHRH-I (mammalian LHRH)
and LHRH-II (chicken LHRH-II) genes were identified.
LHRH-II has been likewise found in tumors such as breast
carcinoma, but the functional receptor for LHRH-II is absent
in humans (1). The human LHRH-I gene is composed of four
exons separated by three introns and is present as a single
gene copy on chromosome 8p11.2-p21 (2,3). Three LHRH
receptors or receptor-like genes were demonstrated earlier
(2-6). The well-established type-I LHRH receptor (LHRH-R-I)
gene has been identified as a single copy on chromosome
4q21.2 (4,5) and is composed of three exons separated by
two introns (6). A vast literature indicates that the LHRH-I is
expressed not only in the hypothalamus but also in peripherial
tissues, both normal and tumoral (7-16). However, only
limited findings are available on the presence of full length
LHRH-R-I and its splice variants or transcript forms in human
malignant and benign tissues (17,18). The LHRH-R-I belongs
to the G protein-coupled receptor (GPCRs) family (19,20)
with seven transmembrane domains (TMs) connected by
extracellular loops (ECLs) and intracellular loops (ICLs).
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LHRH-R-I is expressed on the surface of pituitary gonadotrope
cells (1,19). This receptor is characterized by the unique
absence amongst GPCRs of a carboxyl-terminal tail (21).
LHRH-R-I has much higher affinity for LHRH-I than for
LHRH-II (22-24). Based on their ligand binding proporties
LHRH receptors appear to be quite similar in the human
pituitary, human normal extrapituitary tissues and human
cancers, but their signalling pathways are different (25,26).
In the past 25 years several thousand LHRH analogs have
been synthesized. Many analogs were shown to have important
clinical applications in gynecology, oncology and urology
(1,9,27-29).
Only LHRH-R-I was isolated as a functional receptor in
human tissues. Earlier, three different mRNA products for
LHRH-R-I have been identified (30). Two splice variants of
the LHRH-R-I (LHRH-R-I Sb1), termed Sb2 and Sb3 have
been reported (17,18). The shorter transcript Sb3 contains a
220-bp deletion in exon 2, the other splice variant Sb2 carries
a shorter deletion of 128 bp. The expression of LHRH-R-I
has been demonstrated in normal and malignant tissues by
several groups, although some investigators did not use
primers designed for the full length LHRH-R-I gene (31-33).
The aim of our work was to investigate the mRNA
expression for LHRH-R-I transcript forms in human benign
prostatic hyperplasia (BPH) specimens. Our study was
carried out with previously published primers as well as with
LHRH-R-I specific primers designed by us. LHRH-I receptor
transcripts have been already extensively studied in various
human tissues, including those of the breast, endometrium,
prostate and ovary. In our work, we investigated the mRNA
expression for LHRH-R-I transcript forms in human BPH
specimens using RT-PCR.
Materials and methods
Tissue samples. Human BPH specimens from 35 patients
(mean age, 67.9 years; range, 55-82 years) were collected
at the Department of Urology, University of Debrecen,
Debrecen, Hungary. Approximately 8-10 mm3 of each tissue
was used for molecular biology studies. Histopathological
examinations of each specimen was undertaken to confirm
the presence of benign prostatic hyperplasia (BPH) before
the molecular biology studies. Two normal pituitary samples
were collected at autopsy from the Department of Pathology,
University of Debrecen and were used as positive controls.
After removal, all samples were flash frozen and stored at
-70˚C. The collection of human tissue specimens and the
experimental protocol have been approved by the Institutional
Ethics Committee for the current study and the patients gave
informed consent.
RNA isolation and RT-PCR. Tissues were homogenized with
a Mikro-Dismembrator-U (Sartorius B.Braun Biotech,
Melsunge, Germany) and RNA was extracted with Nucleospin
Total RNA Isolation Kit (Macherey-Nagel, Germany). RNA
concentration and purity were determined using the Nanodrop
ND-1000 UV Spectrophotometer (Nanodrop Technologies,
Wilmington, DE, USA). Total RNA (100-250 ng) was reverse
transcribed to cDNA with MMLV Reverse Transcriptase
(Promega Co., Madison, WI, USA) according to the manu-
facturer's instructions. For amplification from first strand
cDNA gene-specific primers for LHRH-R-I (forward) F1/
(reverse) R1: F1:5'-GACCTTGTCTGGAAAGATCC-3'
(exon 1 1844-1863) and R1: 5'-TGATGGTGGTGATCAGC
CTG-3' (exon 1 2143-2162), LHRH-R-I F2/R3: F2: 5'-AGC
AGACAGCTCTGGACAGACAAAA-3' (exon 2 2300-2322)
and R3: 5'-TGTCTGCTGGACTCCCTACTATGT-3' (exon 3
2582-2605), and beta actin (bACT) housekeeping gene
F3/R4: F3: 5'-GGCATCCTCACCCTGAAGTA-3' (exon 3)
R4: 5'-GGGGTGTTGAAGGTCTCAAA-3' (exon 4) were
described earlier (32,34-36) (Fig. 1). Primers for LHRH-R-I
F1'/R2': F1': 5'-TAGTGTCTTTGCAGGACCACA-3' (exon 1
2262-2273) and R2': 5'-AATCATCTTCACCCTGACACG-3'
(exon 2 2460-2480) were designed using Primer3 (http://www-
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). For
LHRH-R-I F1/R1, LHRH-R-I F1'/R2' and bACT, the PCR
reaction mixture contained 2 μl cDNA, 1.5 mM MgCl2, 0.5 μM
of each primer (Invitrogen), 1X PCR buffer, 200 μM of each
dNTP, and 1 U Taq Polymerase (Invitrogen) in a final volume
of 25 μl. After denaturation (3 min at 94˚C) cDNA was
amplified for 45 cycles (45 sec at 94˚C; 30 sec at 60˚C; and
90 sec at 72˚C), bACT was amplified with 30 cycles, then a
final elongation step at 72˚C for 10 min was applied. 
For LHRH-R-I F2/R3 the PCR reaction mixture contained
2 μl cDNA, 3 mM MgCl2, 0.5 μM of each primer (Invitrogen),
1X PCR buffer, 200 μM of each dNTP, and 1 U Taq Poly-
merase (Invitrogen) in a final volume of 25 μl. After denatu-
ration (3 min at 94˚C) cDNA was amplified for 45 cycles
(45 sec at 94˚C; 30 sec at 66˚C; and 90 sec at 72˚C) and then
a final elongation step at 72˚C for 10 min was applied. PCR
products were separated electrophoretically on 1.5% agarose
gel and stained with ethidium bromide. 
Results
Expression of mRNA for human type-I LHRH receptors in
human benign prostatic hyperplasia. RT-PCR analysis was
carried out to investigate the expression of different LHRH-R
transcript forms in human BPH tissue samples. We used
LHRH-R-I F1/R1 primers encompassing the open reading
frame (ORF) from exon 1 to exon 1, LHRH-R-I F2/R3 from
exon 2 to exon 3 and LHRH-R-I F1'/R2' primers from exon 1
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Figure 1. Nomenclature, sequence and position of forward (F) and reverse (R)
oligonucleotide primers with reference to human LHRH-R-I cDNA sequence
published previously (19,20).
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to exon 2 (Figs. 1 and 2). The predicted size of the PCR-
amplified LHRH-R F1/R1 cDNA was 319 bp for the full-
length transcript (sb1), for the partial exon 2-deleted variant
(sb2) and for the exon 2-lacking (sb3). The predicted size of
the PCR-amplified LHRH-R F2/R3 cDNA was 309 bp for
the full-length transcript (sb1). The predicted size of the
PCR-amplified LHRH-R F1'/R2' cDNA was 219 bp for the
full-length transcript (sb1) and 91 bp for the partial exon 2-
deleted variant (sb2) (Fig. 3). PCR products for LHRH-R-I
F1/R1 were detected in 21 of 35 (60%) human BPH
specimens. PCR products for LHRH-R-I F2/R3 were
detected in 5 of 35 (14%) BPH specimens. We were not able
to demonstrate PCR products for LHRH-R-I F1'/R2' in any
of the BPH samples investigated (Tables I and II). Although
LHRH-R-I transcripts have been previously detected in
extensive series of human tissues (18), in our study we were
not able to find the mRNA for the full length LHRH-R-I
by RT-PCR. PCR amplification with human bACT gene-
specific primers generated a single product of the expected
size of 203 bp in all samples investigated.
Expression of mRNA for human type-I LHRH receptors in
human pituitary tissue. In human pituitary tissue samples,
used as a positive control, we were able to detect the mRNA
for LHRH-R-I transcript forms with all the three primer sets
applied in our study (Fig. 3). We could not detect the partial
exon 2-deleted variant (sb2) using LHRHR-I F1'/R2' primers
in the human pituitary samples investigated. We did not use
specific primers to detect the LHRH-R-I Sb3 that is also a
variant lacking exon 2. 
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Figure 2. Coding nucleotide sequence (CDS:1752-2738) of the human
LHRH-R-I gene. The start and the stop codons are marked with red lower-
case letters. Gene specific primers for LHRH-R-I F1/R1, LHRH-R-I F2/R3
and LHRH-R-I F1'/R2' are marked with blue, green and yellow, respectively.
The nucleotide sequences of the human type-I LHRH receptor (19) were
used to query the human genome sequence using the BLAST search
programs of the National Center for Biotechnology Information (NCBI)
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi).
Figure 3. Representative RT-PCR analysis of mRNA for bACT (panel 1), LHRH-R-I F1/R1 (panel 2), LHRH-R-I F2/R3 (panel 3), LHRH-R-I F1'/R2' (panel 4)
in human BPH specimens and in a human pituitary sample used as positive control. PCR products were separated electrophoretically on 1.5% agarose gel and
stained with ethidium bromide. Lane M, molecular DNA marker (50 bp); lanes 1-4, BPH samples; lane N, no template control; lane P, positive control
(human pituitary tissue).
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Discussion
LHRH agonists have been used extensively for the treatment
of various diseases and medical conditions, in which the
suppression of gonadotropin and/or gonadal steroid hormone
secretion is desired. The possible usefulness of LHRH analogs
in treatment of human benign prostatic hyperplasia based in
part on direct effects is also suggested by numerous reports
(1,9). Experimental and clinical evidence indicates the
existence of a functional LHRH loop, and the presence of
specific LHRH receptors in human BPH (1,9,34). In the
present study, we examined the expression of LHRH-R-I
RÓZSA et al:  LHRH RECEPTORS IN HUMAN BENIGN PROSTATIC HYPERPLASIA1056
Table I. Clinicopathological findings and mRNA expression pattern of LHRH-R-I F1/R1, LHRH-R-I F2/R3 and LHRH-R-I
F1'/R2' in human benign prostatic hyperplasia specimens.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Patient no. Patient age (years) PSA-value (ng/ml) bACT LHRH-R-I F1/R1 LHRH-R-I F2/R3 LHRH-R-I F1'/R2'
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
1. 81 - + + + -
2. 55 0.45 + + - -
3. 82 Normal + + - -
4. 70 3.52 + + + -
5. 71 6.62 + + - -
6. 65 Increased + + + -
7. 73 9.45 + + - -
8. 66 NA + + - -
9. 62 NA + + - -
10. 70 1.12 + + - -
11. 65 NA + + - -
12. 70 0.5 + + - -
13. 56 10-12 + + - -
14. 64 2.4 + + - -
15. 73 1.56 + + - -
16. 76 Normal + + - -
17. 77 0.92 + + - -
18. 55 NA + - - -
19. 67 3.21 + - - -
20. 59 NA + - - -
21. 74 NA + - - -
22. 61 NA + - - -
23. 75 1.57 + + - -
24. 74 3.76 + + - -
25. 75 10.84 + - - -
26. 73 NA + + - -
27. 68 3.84 + - - -
28. 67 NA + - - -
29. 69 NA + - + -
30. 75 NA + - + -
31. 62 NA + + - -
32. 67 0.3 + - - -
33. 58 NA + - - -
34. 76 2.26 + - - -
35. 55 NA + - - -
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
NA, not available.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table II. Expression of mRNA for the bACT, LHRH-R-I
F1/R1, LHRH-R-I F2/R3, and LHRH-R-I F1'/R2' in human
benign prostatic hyperplasia samples.
–––––––––––––––––––––––––––––––––––––––––––––––––
Gene Positive/total % Positive
sample size
––––––––––––––––––––––––––––––––––––––––––––––––– 
bACT 35/35 100
LHRH-R-I F1/R1 21/35 60
LHRH-R-I F2/R3 5/35 14
LHRH-R-I F1'/R2' 0/35 0
––––––––––––––––––––––––––––––––––––––––––––––––– 
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gene in 35 human BPH specimens. Our work represents the
first demonstration of the presence of LHRH-R-I transcripts
in human BPH tissue samples obtained after radical prosta-
tectomy. We were able to detect that the transcripts of
LHRH-R-I were widely distributed in human BPH samples.
In our study, sequences of LHRH-R-I from exon 1 to exon 1
were amplified in 60% of the specimens and sequences
from exon 2 to exon 3 were detected in 14% of the human
BPH tissue samples investigated. However, we could not
find sequences from exon 1 to exon 2 that correspond to
the full-length LHRH-R-I sequences. Our results could be
explained by the fact that LHRH-R-I gene may have more
than two splice variants or other, uncharacterised transcript
forms. We also confirmed the expression of the LHRH-R-I
gene transcripts in human pituitary samples. By alternative
splicing, multiple transcripts can be generated from a single
gene. This represents an important/key molecular mechanism
of gene regulation in physiological and pathophysiological
processes. It is important to note that different transcript
forms of mRNA for LHRH-R-I were expressed in human
BPH specimens, but these transcripts are not the same variants
lacking exon 2. Finch et al (37) suggests that LHRH-R-I
splicing may be regulated in a tissue-specific manner, or
under specific hormonal or metabolic conditions. Generation
of protein isoforms by alternative splicing is known to occur
in numerous members of the G-protein-coupled receptors
family (38-40), correlating with differences in affinity, potency,
coupling efficiency, specificity and sensitivity to desen-
sitization of the receptors. Differential splicing could also
have a physiological significance, as production of a short
transcript was shown to downregulate the level of a wild-type
(WT) transcript (41). Splice variants of peptide hormone
receptors can differ fundamentally from their WT receptor
counterparts in pharmacological and functional characteristics,
in their distribution in normal and malignant human tissues,
and in their potential use for clinical applications. It is well-
established that regulation of splicing may provide another
control mechanism in the expression of the LHRH-R-I gene
in the human pituitary and extrapituitary tissues. Although
LHRH-I receptor transcripts were detected in an extensive
series of human tissues, including those of the breast, uterus,
endometrium, prostate and ovary (42-52), we have been
unable, so far, to find full length LHRH-R-I using RT-PCR
analyses. Although pituitary and extrapituitary LHRH-R-I
transcripts appear identical, their functional characteristics
may differ. In the pituitary, LHRH-R-I are coupled via Gq/11 to
phospho-lipase C (PLC), causing an IP3-mediated mobilization
of Ca2+ and a protein kinase C-mediated activation of MAP
kinases. However, there is little evidence for PLC activation
by endogenous extrapituitary LHRH-R-I (44,48). Instead,
Gi-mediated activation of protein phosphatase and inhibition
of MAP kinase activity may be the basis of some of the anti-
proliferative effects mediated by LHRH-R-I (44,46,52,53).
Investigation of the expression of extrapituitary LHRH-R-I
revealed major functional differences between LHRH-R-I
in human pituitary and extrapituitary sites, in spite of the
expression of identical receptor transcripts (19). In radio-
ligand binding studies (26), pituitary LHRH-R-I displayed
high affinity for agonists such as buserelin [dissociation
constant (Kd) values being in the nM range], whereas some
extrapituitary tissues showed lower affinity (Kd values being
in the μM range). In other reports, it was speculated that
LHRH-R-I activation inhibits proliferation (or causes cell
death) and the identical effects of agonists and antagonists
would apply. Such agonist/antagonist dichotomy can be
defined mainly with pituitary LHRH-R-I, but not with receptors
expressed in extrapituitary sites (26,47,48). The low proportion,
conformation and the numbers/levels of LHRH-R-I in cell
membranes could be important parameters for better under-
standing of the pathophysiological function of LHRH-R-I in
extrapituitary sites (37). Although we failed to detect the full
length LHRH-R-I in human BPH tissues, Kottler et al (18)
demonstrated the presence of different LHRH-R-I transcripts
in a variable percentage of human tumors and non-tumor
tissues. The high incidence of specific, high affinity receptors
for LHRH and the full-length LHRH-R-I mRNA in human
prostate cancers and benign prostatic tissues was also described
earlier (34). At present it is not clear whether alternative
splicing of LHRH-R-I transcripts could play a physiological
role. Alternatively spliced receptor isoforms have been
implicated in altered receptor functions. In the human pituitary
and extrapituitary tissues, including human BPH, the regulation
of splicing might provide another control mechanism in the
expression of the LHRH-R-I gene.
Our findings support the merit of further investigation of
the expression of LHRH-R-I and its transcript forms in human
malignancies as well as the application of LHRH analogues
for receptor-based diagnosis and treatment of human benign
prostatic hyperplasia.
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